Clinical Studies on Ribostamycin sulfate

외과영역에서의 감염증에 대한 Vistamycin 의 사용경험

Ribostamycin sulfate is a new aminoglycoside antibiotic which is effective against organisms resistant to other conventional antibiotics, Particularly E. coli, and Staphylococcus group. Our clinical studies were performed on 20 patients who were admitted to Thoracic Surgical Dept of National Medical Center from May '77 to September '77, and the following results were obtained; 1. Among 20 patients, 13 were excellently improved and 4 responded moderataly, but 3 patients were not improved. So, 85% of the patients were controlled with Ribostamycin sulfate administration. 2. The rate of effectiveness of Ribostamycin sulfate was 85.7% against E. coli, 92.3% against Staphylococcus, and 75% against klebsiella, revealing 83.3% in average. 3. No side effects were observed. 4. From our clinical studies, Ribostamycin sulfate is expected to possess in high therapeutic value in surgical infectins caused by both gram positive and negative microorganisms.